GNBT .69 didn't quite get down to my .62 target, but they've been making some good moves lately, including getting ready to market in Latin America, with a recent hire.
There is a CC at 2 which may shed some light. I know they are desperately trying to get the stock to a buck to avoid delisting. I think they have 1 more extension, but not sure.
Great potential products, delivery of insulin, pain killers, etc., orally, but crappy management, maybe worth a shot at this price.
Generex Biotechnology Corp. to Host Call Today to Update Investors on Commercialization of Oral-lyn(TM)
PR Newswire - September 27, 2005 11:33
Conference Call and Webcast to Take Place at 2 pm Eastern Time today
TORONTO, Sept 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), a leader in the area of buccal drug delivery, announced today that it will hold a conference call and webcast at 2 pm eastern time today to update interested parties on commercialization plans for Oral-lyn(TM), its proprietary oral insulin product which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and is in various stages of clinical trials around the world.
Interested parties should call (877) 405-4114, or (706) 643-7496 for international participants. Please reference Conference I.D. Number 9981199.
There will be a playback available until midnight, October 27, 2005. To listen to the playback, please call (800) 642-1687 or (706) 645-9291. Please use pass code 9981199 for the replay.
This call is being webcast and can be accessed at the Company's web site at audioevent.mshow.com or generex.com until October 27, 2005.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. |
